Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic ...

Prime Medicine’s prime editors have corrected a gene mutation in primates that causes a rare liver disease, a step toward taking the tech to humans. In an Oct. 27 presentation at the annual European ...

The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...

Despite the copious demands of his administrative positions as the White House chief science advisor (and until last year, the director of the NIH), Francis Collins, MD, PhD, has continued to run a ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

While Kiran Musunuru, MD, PhD, is already in the process of using prime editing—a search and replace genome editing technology that doesn’t create double-strand breaks or use donor DNA—in his academic ...

Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor ...

Scientists showed how prime editing can correct mutations that cause sickle cell disease in a potentially curative approach. Sickle cell disease (SCD) is a serious blood disorder affecting millions of ...

Scientists at The Broad Institute of MIT and Harvard and The Jackson Laboratory have used a precise form of gene editing to target the underlying mutations behind the rare neurological disorder, ...